Exhibitor profile
Dawnrays Pharmaceutical (Holdings) Ltd.
—— Attend To Health Persist In Creation
China will be the fifth largest pharmaceutical market by 2010 and Mainland China the top destination for the investment of foreign pharmaceutical companies. Leading pharmaceutical companies invest more in China in 2007. Eli Lilly established its Lilly Asian Ventures in 2007 with a geographic focus on east and south Asia, particularly India and China; Roche announced the plan to establish drug development center in China; Johnson & Johnson (China) , a wholly owned subsidiary of Johnson & Johnson, plans to buy more shares in Xi'an-Janssen Pharmaceutical from the latter's Chinese shareholders. These pharmaceutical giants are catching China opportunities in VC, R&D, manufacture, and sales, and local Asian players determines not to lag behind. Dawnrays Pharmaceutical (Suzhou, China) is a good example in case.
Dawnrays Pharmaceutical (Holdings) Ltd. (HXEx: 02348 ) has 6 subsidiaries: Suzhou Dawnrays Pharmaceuticals, Suzhou Dawnrays Chemical, Shanghai Dawnrays Chemical , Dawnrays Pharma Tech(Nantong), Dawnrays Pharma (Hong Kong), and Guandong Dawnrays Pharmaceutical.
Dawnrays Pharmaceutical (Holdings) Ltd. focuses on the R&D, manufacture, and sales of cef- antibiotics and specialty drugs. Its antibiotics include intermediates, APIs, fixed dose drugs, and its specialty drugs cover anti-allergic, cardiovascular, digestive, urinary, and endocrine drugs in troche, capsules, and granulate forms.
In the section of cef-antibiotics, the company has integrated the production chain of intermediates, APIs, and fixed-dose drugs. It is the first Chinese company that manufactures cef－ products via solvent crystallization. Backed by its advanced technology platform for the synthesis of cephalosporin, the company has formed cef- product line of rich product varieties, complete accessory functions, and adequate capacity potential. The quality of the products reaches leading international standard. Dawnrays has established its presence in the fields of cardiovascular and endocrine drugs. Its Amlozen® (Amlodipine Besylate) tablets and Cecoride® (Cetirizine Hydrochloride ) tablets have good market shares.
Dawnrays Pharmaceutical donated RMB 1.2 million worth of much-needed drugs to help those suffer from the May 12 earthquake that hit Wenchuan of Sichuan province, China. The drugs include Cepcal®(ceftriaxone sodium for injection),Cepchine®(cefotaxime sodium for injection), azithromycin tablets, and roxithromycin tablets.
Dawnrays is committed to improving human health. With social responsibility and preemptive thoughts in mind, it keeps innovation and offers safe and effective products. It is aimed at becoming the top pharmaceutical company in China and contributing to human health.
Welcome to No. E2G22
